Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the ‘Real-Life’ Setting

Immune checkpoint inhibitors (ICIs) are now the standard of care for metastatic urothelial carcinoma (mUC) patients. Our aim was to describe the activity of ICIs in mUC and find the clinical parameters associated with response. This is a retrospective, single-center chart review of mUC patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadot, Moran, Arad, Ido, Atenafu, Eshetu G., Levartovsky, Meital, Portnoy, Orith, Davidson, Tima, Schor-Bardach, Rachel, Berger, Raanan, Leibowitz, Raya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504505/
https://www.ncbi.nlm.nih.gov/pubmed/36145376
http://dx.doi.org/10.3390/ph15091154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504505/
https://www.ncbi.nlm.nih.gov/pubmed/36145376
http://dx.doi.org/10.3390/ph15091154

Ejemplares similares